• Dogwood Therapeutics launched a Phase 2b open-label extension study of Halneuron for chemotherapy-induced neuropathic pain, enrolling patients who complete its ongoing 4-week double-blind trial.
• Results from the extension study will be presented in the future, with the main 4-week trial still expected to deliver top-line results in fall 2026.
• The new 12-week follow-on trial aims to show whether pain relief can be sustained with longer treatment while expanding the safety profile, supporting an end-of-Phase 2 FDA package.
• An interim assessment from the ongoing study has already indicated a favorable treatment effect versus placebo, backing continued development and informing plans for a Phase 3 program targeted to start in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180845PRIMZONEFULLFEED9721866) on May 18, 2026, and is solely responsible for the information contained therein.